The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published on October 14
The FDA's approval of blood-based Alzheimer's testing marks the first time primary care doctors can easily screen for the disease. This accessibility could transform how millions of patients are diagnosed and treated.
Early detection capabilities are expected to dramatically expand the addressable patient population for Alzheimer's treatments. Companies positioned in this space could see significant growth as diagnosis moves from specialist centres to everyday healthcare.
With Roche and Eli Lilly leading this diagnostic revolution, companies in this curated group are positioned to capitalise on the paradigm shift before it becomes mainstream. Early positioning could yield substantial returns.
The FDA's approval of blood-based Alzheimer's testing represents a paradigm shift from expensive, complex procedures to accessible primary care diagnosis. This breakthrough creates significant market expansion opportunities for both diagnostic companies and pharmaceutical firms developing treatments for a newly identifiable patient population.
This group focuses on companies positioned to benefit from the transition to early, accessible Alzheimer's diagnosis. The theme includes diagnostic specialists, laboratory services providers, and pharmaceutical developers whose treatments become more viable with earlier patient identification and larger addressable markets.
These companies were handpicked by professional analysts based on their strategic positioning within the evolving Alzheimer's diagnostic and treatment landscape. Each firm offers tactical exposure to the biotechnology and healthcare sectors, specifically targeting those poised to capitalise on this regulatory milestone and innovation catalyst.
This basket totals $815.41B in market capitalisation and is heavily concentrated in one very large constituent, producing a stable, lower-risk posture compared with small-cap-oriented baskets.
LLY: $775.53B
BIIB: $21.21B
SAVA: $198.06M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
Current Price
$1,115.23
Eli Lilly received FDA approval alongside Roche for the groundbreaking Elecsys pTau181 blood test, positioning the company at the forefront of accessi...
Eli Lilly received FDA approval alongside Roche for the groundbreaking Elecsys pTau181 blood test, positioning the company at the forefront of accessible Alzheimer's diagnosis.
ANAVEX LIFE SCIENCES CORPORATION
AVXL
Current Price
$2.62
Anavex Life Sciences focuses on neurodegenerative disease treatments that could see expanded market opportunities through improved early detection cap...
Anavex Life Sciences focuses on neurodegenerative disease treatments that could see expanded market opportunities through improved early detection capabilities.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+284.61%
On average, analysts expect assets in this group to grow 284.61% over the next year.
11 of 13 assets in this group are rated Buy by professional analysts.
